In the wake of the increase in Current Liabilities in the fourth quarter 2026, Quick Ratio fell to 2.57 below Briacell Therapeutics Corp average.

Within Major Pharmaceutical Preparations industry 160 other companies have achieved higher Quick Ratio than Briacell Therapeutics in fourth quarter 2026. While Quick Ratio total ranking in the fourth quarter 2026 has deteriorated compared to the prior quarter from 367 to 691.

Explain Quick Ratio?
How much Cash & cash equivalents BCTX�s has?
What are BCTX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/BCTX/financial-strength

https://api.csimarket.com/api/v1/companies/BCTX/fundamentals

https://api.csimarket.com/api/v1/companies/BCTX/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

BCTX Quick Ratio	(Jul 31 2026) Q4	(Apr 30 2026) Q3	(Jan 31 2026) Q2	(Oct 31 2025) Q1	(Jul 31 2025) Q4
Y / Y Current Liabilities Change	100.64 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	14.97 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	2.57	Subscribe	Subscribe	Subscribe	Subscribe
BCTX's Total Ranking	# 691	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	122.3 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-9.93 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio fourth quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 161
Healthcare Sector	# 258
Overall Market	# 691

Quick Ratio Statistics
High	Average	Low
202.9	35.01	0.01
(Jan 31 2022)		(Jul 31 2020)

Financial Statements
Briacell Therapeutics 's Current Liabilities	$ 8 Millions	Visit BCTX's Balance sheet
Briacell Therapeutics 's Cash & cash equivalent	$ 21 Millions	Visit BCTX's Balance sheet
Source of BCTX's Sales		Visit BCTX's Sales by Geography

Cumulative Briacell Therapeutics 's Quick Ratio

BCTX's Quick Ratio for the trailling 12 Months

BCTX Quick Ratio	(Jul 31 2026) 12 Months	(Apr 30 2026) 12 Months	(Jan 31 2026) 12 Months	(Oct 31 2025) 12 Months	(Jul 31 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-2.44 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	102.82 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	4.62	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 2889	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	28.45 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	3.31 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to BCTX Financial Strength Comparisons >> Go to Compare BCTX Quick Ratio to its Competitors

News about Briacell Therapeutics Corp Quick Ratio

BriaCells Bria-OTS Pioneering a Personalized Approach in Metastatic Breast Cancer Treatment,

Revolutionary Steps in Metastatic Breast Cancer Treatment: BriaCell s Innovative Bria-OTS Study Begins In a significant breakthrough for metastatic breast cancer treatment, BriaCell Therapeutics Corp. a dynamic force in the biotech industry, has announced the dosing of the first patient in its groundbreaking Phase 1/2 study. This milestone marks the debut of Bria-OTS, BriaCell s latest personalized next-generation immunotherapy that promises a new horizon in the battle against cancer.The study, registered under ClinicalTrials.gov identifier NCT06471673, undertakes a rigorous evaluation of the safety and efficacy of Bria-OTS. This cutting-edge therapeutic approach is designed to tailor treatment uniquely to each patient s cancer profile, potentially transforming how metastatic breast cancer is managed. The study also explores the potential of using Bria-OTS in combination with the immune checkpoint inhibitor tislelizumab, in collaboration with BeiGene, Ltd.

On the trailing twelve months basis Due to in Current Liabilities in the Q4 2026 to $7.98 millions, cumulative Quick Ratio decreased to 4.62 below the average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 396 other companies have achieved higher Quick Ratio than Briacell Therapeutics . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2026 from 2366 to 2889.

Explain Quick Ratio?
How much Cash & cash equivalents BCTX�s has?
What are BCTX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 397
Healthcare Sector	# 802
Within the Market	# 2889

trailing twelve months Quick Ratio Statistics
High	Average	Low
35.32	8.49	0.52
(Apr 30 2023)		(Jan 31 2025)

Companies with similar Quick Ratio in the quarter ending Jul 31 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jul 31 2026 MRQ Cash & cash equivalent	Jul 31 2026 MRQ Current Liabilities
Arvinas Inc	6.88	$ 567.900 Millions	$ 82.500 Millions
Alumis inc	6.59	$ 502.300 Millions	$ 76.233 Millions
Novelos Therapeutics, Inc.	6.49	$ 33.994 Millions	$ 5.238 Millions
Genprex Inc	6.47	$ 15.154 Millions	$ 2.342 Millions
Lisata Therapeutics Inc	6.45	$ 19.277 Millions	$ 2.987 Millions
Larimar Therapeutics Inc	6.44	$ 219.880 Millions	$ 34.166 Millions
United Therapeutics Corporation	6.13	$ 3,724.700 Millions	$ 607.800 Millions
Serina Therapeutics Inc	6.12	$ 23.024 Millions	$ 3.762 Millions
Revelation Biosciences Inc	6.11	$ 11.483 Millions	$ 1.880 Millions
Spero Therapeutics Inc	6.02	$ 50.774 Millions	$ 8.428 Millions
Aquestive Therapeutics Inc	5.98	$ 98.490 Millions	$ 16.478 Millions
Xencor Inc	5.94	$ 486.350 Millions	$ 81.865 Millions
Zymeworks Inc	5.73	$ 270.699 Millions	$ 47.243 Millions
Tonix Pharmaceuticals Holding Corp	5.72	$ 176.232 Millions	$ 30.785 Millions
Emmis Acquisition Corp	5.72	$ 0.708 Millions	$ 0.124 Millions
Arcturus Therapeutics Holdings Inc	5.71	$ 191.483 Millions	$ 33.536 Millions
Hoth Therapeutics Inc	5.70	$ 7.892 Millions	$ 1.384 Millions
Silence Therapeutics Plc	5.67	$ 72.054 Millions	$ 12.714 Millions
Adial Pharmaceuticals Inc	5.51	$ 28.200 Millions	$ 5.121 Millions
Corbus Pharmaceuticals Holdings Inc	5.49	$ 117.941 Millions	$ 21.483 Millions
Bio Green Med Solution Inc	5.48	$ 3.790 Millions	$ 0.692 Millions
Arrowhead Pharmaceuticals Inc	5.47	$ 1,551.301 Millions	$ 283.346 Millions
Context Therapeutics Inc	5.45	$ 42.990 Millions	$ 7.885 Millions
Annexon Inc	5.44	$ 209.200 Millions	$ 38.482 Millions
Arbutus Biopharma Corp	5.35	$ 19.172 Millions	$ 3.585 Millions
Cns Pharmaceuticals Inc	5.35	$ 19.985 Millions	$ 3.738 Millions
Neurogene Inc	5.23	$ 112.485 Millions	$ 21.505 Millions
Lexaria Bioscience Corp	5.20	$ 3.642 Millions	$ 0.701 Millions
Barinthus Biotherapeutics Plc	5.19	$ 59.295 Millions	$ 11.423 Millions
Lite Strategy Inc	5.15	$ 5.706 Millions	$ 1.109 Millions

Date modified: 2026-10-29T09:57:09+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.